UTHR UNITED THERAPEUTICS Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1082554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.9%
TTM net income YoY-3.2%
TTM EPS YoY0.4%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR11.0%
Margins
Gross margin86.3%
Operating margin41.4%
Net margin38.6%
FCF margin27.2%
EBITDA margin44.5%
Returns
ROE19.1%
ROA17.1%
ROIC (approx.)20.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets10.8%
Debt / equity0.00x
Current ratio4.61x
Interest coverage111.02x
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue17.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Cost of revenue | $384.40M | $309.70M | $257.50M | $151.60M | $122.50M |
| Gross profit | $2.80B | $2.57B | $2.07B | $1.78B | $1.56B |
| R&D expense | $550.00M | $481.00M | $408.00M | $322.90M | $540.10M |
| SG&A expense | $755.80M | $709.70M | $477.10M | $482.10M | $467.00M |
| Operating income | $1.49B | $1.38B | $1.18B | $979.70M | $555.90M |
| Interest expense | $19.50M | $42.90M | $59.30M | $32.40M | $18.60M |
| Pretax income | $1.71B | $1.54B | $1.27B | $950.60M | $593.90M |
| Income tax | $379.20M | $343.90M | $289.50M | $223.30M | $118.10M |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M |
| EBITDA | $1.58B | $1.45B | $1.24B | $1.03B | $605.80M |
| EPS (basic) | 30.13 | 26.44 | 21.04 | 15.98 | 10.60 |
| EPS (diluted) | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 |
| Weighted avg. shares (diluted) | 47.90M | 48.50M | 49.70M | 48.50M | 47.30M |
| Balance sheet | |||||
| Cash & equivalents | $1.56B | $1.70B | $1.21B | $961.20M | $894.80M |
| Short-term investments | $1.36B | $1.57B | $1.79B | $1.88B | $1.04B |
| Receivables | $350.20M | $279.30M | $278.90M | $220.40M | $198.70M |
| Inventory | $183.10M | $157.90M | $111.80M | $102.00M | $93.80M |
| Current assets | $3.70B | $3.87B | $3.55B | $3.38B | $2.32B |
| PP&E, net | $1.73B | $1.22B | $1.05B | $861.50M | $780.90M |
| Goodwill | $32.30M | $32.30M | $33.70M | $28.00M | $28.00M |
| Total assets | $7.88B | $7.36B | $7.17B | $6.04B | $5.17B |
| Current liabilities | $560.60M | $738.10M | $804.40M | $343.20M | $305.40M |
| Total liabilities | $783.80M | $920.00M | $1.18B | $1.25B | $1.21B |
| Shareholders' equity | $7.10B | $6.44B | $5.98B | $4.80B | $3.96B |
| Shares outstanding | 43.64M | 44.83M | 47.04M | 46.03M | 45.11M |
| Cash flow statement | |||||
| Operating cash flow | $1.56B | $1.33B | $978.00M | $802.50M | $598.20M |
| Capital expenditure | $520.50M | $246.50M | $230.40M | $138.80M | $120.80M |
| Free cash flow | $1.04B | $1.08B | $747.60M | $663.70M | $477.40M |
| Investing cash flow | -$551.30M | $417.20M | -$719.60M | -$811.50M | -$486.90M |
| Financing cash flow | -$1.15B | -$1.25B | -$11.90M | $75.40M | $44.80M |
| Depreciation & amortization | $85.60M | $72.50M | $53.20M | $51.30M | $49.90M |
| Stock-based compensation | $147.70M | $144.00M | $39.10M | $106.80M | $138.50M |
| Share buybacks | $1.00B | $1.00B | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.